1. Home
  2. PAMT vs GLSI Comparison

PAMT vs GLSI Comparison

Compare PAMT & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PAMT CORP

PAMT

PAMT CORP

HOLD

Current Price

$12.50

Market Cap

275.4M

Sector

Industrials

ML Signal

HOLD

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$15.09

Market Cap

244.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAMT
GLSI
Founded
1980
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
275.4M
244.7M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
PAMT
GLSI
Price
$12.50
$15.09
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$13.00
$50.00
AVG Volume (30 Days)
15.3K
111.6K
Earning Date
05-12-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$437,838,000.00
N/A
Revenue This Year
$20.12
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.15
N/A
52 Week Low
$7.15
$7.78
52 Week High
$17.75
$34.10

Technical Indicators

Market Signals
Indicator
PAMT
GLSI
Relative Strength Index (RSI) 47.01 43.48
Support Level $10.69 $14.63
Resistance Level $13.04 $29.89
Average True Range (ATR) 0.85 1.52
MACD 0.14 -0.12
Stochastic Oscillator 67.26 14.94

Price Performance

Historical Comparison
PAMT
GLSI

About PAMT PAMT CORP

PAMT Corp is a holding company that is engaged in providing truckload dry van carrier services transporting general commodities throughout the continental United States and Mexico, as well as in certain Canadian provinces. Its freight consists of automotive parts, expedited goods, consumer goods, such as general retail store merchandise, and manufactured goods, such as heating and air conditioning units. It has one reportable segment being motor carrier.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.

Share on Social Networks: